

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (previously amended) A polypeptide which comprises:
  - a) the amino acid sequence of SEQ ID NO: 2;
  - b) an amino acid sequence having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence of SEQ ID NO: 2; or
  - c) an amino acid sequence comprising a fragment of the polypeptide as defined in a) or b) above, which is at least ten amino acids long and comprises amino acids 73-86 of SEQ ID NO.: 2.
2. (original) A polypeptide as claimed in claim 1 which is provided as part of a fusion polypeptide.
3. (original) A polypeptide as claimed in claim 2 wherein the fusion polypeptide comprises Green Fluorescent Protein or the DsRed Fluorescent Protein.
4. (cancelled)
5. (cancelled)
6. (cancelled)
7. (previously amended) A polypeptide which comprises:
  - a) the amino acid sequence of SEQ ID NO: 4;
  - b) an amino acid sequence having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence of SEQ ID NO: 4; or
  - c) an amino acid sequence comprising a fragment of the polypeptide as defined in a) or b) above, which is at least ten amino acids long and comprises amino acids 194 to 203 of SEQ ID NO.: 4.

8. (original) A polypeptide as claimed in claim 7 which is provided as part of a fusion polypeptide.
9. (original) A polypeptide as claimed in claim 8 wherein the fusion polypeptide comprises Green Fluorescent Protein or the DsRed Fluorescent Protein.
10. (cancelled)
11. (cancelled)
12. (cancelled)
13. (cancelled)
14. (cancelled)
15. (cancelled)
16. (cancelled)
17. (cancelled)
18. (cancelled)
19. (cancelled)
20. (cancelled)
21. (cancelled)
22. (cancelled)
23. (cancelled)
24. (currently amended) A pharmaceutical formulation comprising at least one polypeptide, wherein the polypeptide is selected from:
  - a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2;
  - b) a polypeptide comprising an amino acid sequence having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence of SEQ ID NO: 2; and

- c) a polypeptide comprising an amino acid sequence comprising a fragment of the polypeptide as defined in a) or b) above, which is at least ten amino acids long and comprises amino acids 73-86 of SEQ ID NO: 2;
- d) ~~a polypeptide comprising the amino acid sequence of SEQ ID NO: 4;~~
- e) ~~a polypeptide comprising an amino acid sequence having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence of SEQ ID NO: 4; and~~
- f) ~~a polypeptide comprising an amino acid sequence comprising a fragment of the polypeptide as defined in d) or e) above, which is at least ten amino acids long and comprises amino acids 194-203 of SEQ ID NO: 4,~~

optionally together with one or more pharmaceutically acceptable excipients, carriers or diluents.

25. (original) A pharmaceutical formulation as claimed in claim 24, wherein the pharmaceutical formulation is a vaccine.

26. (original) A pharmaceutical formulation as claimed in claim 25, which comprises one or more suitable adjuvants.

27. (cancelled)

28. (cancelled)

29. (cancelled)

30. (new) A pharmaceutical formulation comprising at least one polypeptide, wherein the polypeptide is selected from:

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 4;
- b) a polypeptide comprising an amino acid sequence having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence of SEQ ID NO: 4; and
- c) a polypeptide comprising an amino acid sequence comprising a fragment of the polypeptide as defined in d) or e) above, which is at least ten amino acids long and comprises amino acids 194 to 203 of SEQ ID NO: 4,

optionally together with one or more pharmaceutically acceptable excipients, carriers or diluents.

31. (new) A pharmaceutical formulation as claimed in claim 30, wherein the pharmaceutical formulation is a vaccine.

32. (new) A pharmaceutical formulation as claimed in claim 31, which comprises one or more suitable adjuvants.